Loading company
$56.67-2.8%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Past performance
- 1W
- +1.1%
- 1M
- +2.8%
- 3M
- -15.9%
- 6M
- +6.4%
- 1Y
- +3.5%
- 5Y
- -30.5%
Built from BioMarin Pharmaceutical Inc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$56.67-2.8%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Just reported
From BioMarin Pharmaceutical's results release of November 2, 2026; its quarterly report has since been filed.
Actual
$1.02B
+32% y/y
+3.5% q/q
Guided
—
No guide given
Actual
-$0.63
Guided
—
No guide given
Actual
-$82.1M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes BioMarin Pharmaceutical is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of BioMarin Pharmaceutical Inc’s grade history. The other 39 go back to November 2016.
